US · SABS
SAB Biotherapeutics, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Sioux Falls, SD 57104
- Website
- sabbiotherapeutics.com
Price · as of 2024-12-31
$3.47
Market cap 39.19M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $12.82 | +269.45% |
| Intrinsic Value(DCF) | $0.65 | -81.27% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | $114.47 | +3,198.88% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | $98.90 | $931.13 | $246,250.56 | $32.11 | $6,699.08 |
| 2021 | $19.60 | $383.07 | $4.11 | $0.00 | $0.00 |
| 2022 | $5.57 | $3,811.69 | $0.00 | $0.00 | $215.43 |
| 2023 | $5.36 | $17.65 | $2.57 | $0.00 | $600.16 |
| 2024 | $1.62 | $12.82 | $0.00 | $0.00 | $114.47 |
AI valuation
Our deep-learning model estimates SAB Biotherapeutics, Inc.'s (SABS) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $12.82
- Current price
- $3.47
- AI upside
- +269.45%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$0.65
-81.27% upside
Graham-Dodd
—
— upside
Graham Formula
$114.47
+3,198.88% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| SABS | SAB Biotherapeutics, Inc. | $3.47 | 39.19M | +269% | -81% | — | +3,199% | -0.44 | 0.58 | 11.35 | 0.04 | — | 0.58 | -262.41% | -3244.87% | -2579.03% | -81.92% | -519.55% | -53.23% | 0.18 | -134.77 | 2.98 | 2.61 | 0.15 | -5183.00% | -4094.00% | 3679.00% | -230.79% | -4.30 | -419.29% | 0.00% | 0.00% | 0.00% | 0.03 | 0.03 | -0.82 | -6.18 |
| ANTX | AN2 Therapeutics, Inc. | $1.10 | 30.14M | — | — | — | — | -0.76 | 0.48 | — | -13.78 | — | 0.48 | 0.00% | — | — | -49.69% | -697.76% | -44.47% | 0.00 | — | 8.43 | 8.20 | -6.60 | -3723.00% | — | -756.00% | -126.06% | -4.81 | -630.01% | 0.00% | 0.00% | 14.60% | 0.82 | 0.90 | — | -1.80 |
| BOLD | Boundless Bio, Inc. | $1.16 | 25.97M | — | — | — | — | -0.44 | 0.19 | — | 1.18 | -0.60 | 0.19 | 0.00% | — | — | -554.86% | 73.46% | -38.87% | 0.32 | — | 18.98 | 18.70 | -0.33 | 7342.00% | — | 3346.00% | -220.80% | -7.48 | 63.54% | 0.00% | 0.00% | 0.00% | 1.03 | 1.20 | — | -1.38 |
| EVAX | Evaxion Biotech A/S | $3.16 | 19.96M | +25,906% | -76% | — | — | -0.19 | -1.22 | 0.60 | -0.72 | — | -1.22 | 100.00% | -440.55% | -316.00% | 331.20% | -693.28% | -83.29% | -6.11 | -15.31 | 2.01 | 1.58 | -0.52 | -6975.00% | 448082.00% | -2721.00% | -641.54% | -2.96 | -654.36% | 0.00% | 0.00% | 11.80% | -0.48 | -0.55 | 2.11 | -16.41 |
| GBIO | Generation Bio Co. | $5.34 | 35.98M | +46% | -60% | — | — | -0.27 | 0.41 | 1.78 | 0.76 | -40.69 | 0.41 | 100.00% | -715.82% | -661.91% | -91.02% | -912.79% | -43.46% | 1.09 | — | 5.50 | 5.33 | -0.23 | 66.00% | 23692.00% | 5125.00% | -256.40% | -2.53 | -583.12% | 0.00% | 0.00% | 39.99% | 0.39 | 0.62 | -2.82 | -5.24 |
| ITRM | Iterum Therapeutics plc | $0.26 | 13.97M | — | — | — | — | -1.10 | -6.66 | — | -2.24 | — | -1.14 | 0.00% | — | — | 472.61% | -628.33% | -69.93% | -11.16 | — | 1.41 | 1.37 | -0.99 | -5743.00% | — | -3195.00% | -98.48% | -1.52 | -899.75% | 0.00% | 0.00% | 0.00% | -2.60 | -1.82 | — | -16.11 |
| JSPR | Jasper Therapeutics, Inc. | $1.38 | 22.43M | — | — | — | — | -1.10 | 1.27 | — | -0.11 | — | 1.27 | 0.00% | — | — | -101.73% | 1104.03% | -81.55% | 0.03 | — | 4.98 | 4.70 | 0.93 | -2087.00% | — | 2067.00% | -80.64% | -4.11 | 914.55% | 0.00% | 0.00% | 0.00% | -0.11 | -0.13 | — | -3.88 |
| NXTC | NextCure, Inc. | $12.72 | 34.09M | — | — | — | — | -0.38 | 0.32 | — | 0.77 | — | 0.32 | 0.00% | — | — | -61.87% | -769.60% | -53.28% | 0.09 | — | 7.50 | 7.20 | 0.40 | -1168.00% | — | -2326.00% | -196.82% | -4.26 | -531.71% | 0.00% | 0.00% | 72.95% | 0.70 | 1.01 | — | -7.28 |
| PLUR | Pluri Inc. | $3.60 | 29.39M | +873% | -44% | — | — | -1.37 | -4.65 | 23.81 | -2.05 | — | -2.49 | 48.95% | -1659.88% | -1690.34% | 689.30% | -701.84% | -59.46% | -4.98 | -25.40 | 0.68 | 0.66 | -1.28 | -1078.00% | 30982.00% | 810.00% | -62.33% | -0.56 | -627.70% | 0.00% | 0.00% | 0.00% | -2.04 | -2.28 | 33.87 | -17.73 |
| QTTB | Q32 Bio Inc. | $4.56 | 56.11M | +726% | — | — | — | -0.57 | 4.77 | — | 0.71 | — | 4.77 | 0.00% | — | — | 53.86% | 62.63% | -68.49% | 3.33 | -220.34 | 4.97 | 4.77 | 1.30 | -6060.00% | -10000.00% | 26286.00% | -250.34% | -4.11 | 64.23% | 0.00% | 0.00% | 311.27% | 0.48 | 0.47 | — | -4.89 |
| VRCA | Verrica Pharmaceuticals I… | $5.47 | 51.91M | +100% | -56% | — | — | -0.41 | -3.19 | 4.16 | -0.47 | — | -3.19 | 63.79% | -871.25% | -1012.15% | -1546.58% | 907.73% | -112.84% | -4.66 | -7.00 | 1.76 | 1.60 | 0.01 | 0.00% | 4766.00% | 5654.00% | -193.51% | -2.10 | 839.36% | 0.00% | 0.00% | 0.00% | -0.47 | -0.51 | 4.11 | -11.03 |
About SAB Biotherapeutics, Inc.
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at specific diseases, including infectious diseases comprising COVID-19 and influenza, immune and autoimmune disorders, such as type 1 diabetes, organ transplantation, and cancer. The company uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors. Its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic candidate that is in Phase III clinical trial for the treatment of COVID-19; and SAB-176, a fully-human polyclonal antibody therapeutic candidate that is in development to treat or prevent severe influenza. The company's pre-clinical product candidates in development for autoimmune diseases include SAB-142 for type 1 diabetes and organ transplant induction/rejection. The company was founded in 2014 and is based in Sioux Falls, South Dakota.
- CEO
- Samuel J. Reich
- Employees
- 63
- Beta
- 0.60
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($0.65 ÷ $3.47) − 1 = -81.27% (DCF, example).